# iPierian

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ipierian

- Industry: Pharmaceuticals
- Headquarters: San Francisco, US
- Website: www.ipierian.com
- Total disclosed funding: $60M
- Latest round: Series B (Nov 8, 2010)
- Investors on record: 9

## About

Founded in 2007, iPierian is a San Francisco-based biopharmaceutical company focused on the industrialization of induced pluripotent stem cell (iPSC) technology and the discovery and development of innovative therapeutics using patient-derived cells as models of human disease.

## Funding rounds

- Series B, Nov 8, 2010, $0.5M — Highland Capital Partners, Kleiner Perkins, MPM BioImpact
- Series B, Sep 8, 2010, $6M — SR One, Biogen Idec New Ventures
- Series B, Jul 8, 2010, $22M — Highland Capital Partners, Kleiner Perkins, MPM BioImpact, ATEL Capital Group, FGF Management, GV, Mitsubishi UFJ Capital
- Series A, Jul 3, 2009, $12M — MPM BioImpact, FGF Management
- Series A, May 31, 2009, $10M — Highland Capital Partners, Kleiner Perkins
- Series A, Sep 8, 2008, $5M — Highland Capital Partners
- Series A, Mar 31, 2008, $5.1M — Highland Capital Partners

## Investors

- Highland Capital Partners (https://capitalatlas.ai/funds/highland-capital-partners) — Series A, Series B
- Kleiner Perkins (https://capitalatlas.ai/funds/kleiner-perkins) — Series A, Series B
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series A, Series B
- FGF Management (https://capitalatlas.ai/funds/fgf-management) — Series A, Series B
- ATEL Capital Group (https://capitalatlas.ai/funds/atel-capital-group) — Series B
- GV (https://capitalatlas.ai/funds/gv) — Series B
- Mitsubishi UFJ Capital (https://capitalatlas.ai/funds/mitsubishi-ufj-capital) — Series B
- SR One (https://capitalatlas.ai/funds/sr-one) — Series B
- Biogen Idec New Ventures (https://capitalatlas.ai/funds/biogen-idec-new-ventures) — Series B